212 related articles for article (PubMed ID: 7172502)
21. Interferon decreases production of hydrogen peroxide by macrophages: correlation with reduction of suppressive capacity and of anti-microbial activity.
Boraschi D; Ghezzi P; Pasqualetto E; Salmona M; Nencioni L; Soldateschi D; Villa L; Tagliabue A
Immunology; 1983 Nov; 50(3):359-68. PubMed ID: 6354920
[TBL] [Abstract][Full Text] [Related]
22. Defective tumoricidal capacity of macrophages from P/J mice: tumoricidal defect involves abnormalities in lymphokine-derived activation stimuli and in mononuclear phagocyte responsiveness.
Boraschi D; Meltzer MS
J Immunol; 1980 Aug; 125(2):777-82. PubMed ID: 6993563
[No Abstract] [Full Text] [Related]
23. Antibody-dependent cellular cytotoxicity against tumor cells. II. The promonocyte identified as effector cell.
Domzig W; Lohmann-Matthes ML
Eur J Immunol; 1979 Apr; 9(4):267-72. PubMed ID: 467490
[TBL] [Abstract][Full Text] [Related]
24. A novel rat monoclonal antibody reactive with murine tumoricidal Kupffer cells and activated peritoneal macrophages from BCG-infected mice.
Someya A
Immunology; 1986 Apr; 57(4):605-10. PubMed ID: 2420709
[TBL] [Abstract][Full Text] [Related]
25. Role of endotoxin in the expression of human monocyte cytotoxicity.
Biondi A; Peri G; Lorenzet R; Fumarola D; Mantovani A
J Reticuloendothel Soc; 1983 Apr; 33(4):315-27. PubMed ID: 6187919
[TBL] [Abstract][Full Text] [Related]
26. Similarities among factors that render macrophages tumoricidal in lymphokine and interferon preparations.
Schultz RM; Chirigos MA
Cancer Res; 1978 Apr; 38(4):1003-7. PubMed ID: 346202
[TBL] [Abstract][Full Text] [Related]
27. Antibody-dependent cellular cytotoxicity against tumor cells. I. Cultivated bone marrow-derived macrophages kill tumor targets.
Lohmann-Matthes ML; Domzig W; Taskov H
Eur J Immunol; 1979 Apr; 9(4):261-6. PubMed ID: 467489
[TBL] [Abstract][Full Text] [Related]
28. Relationship between murine macrophage Fc receptor-mediated phagocytic function and competency for activation for non-specific tumor cytotoxicity.
Leu RW; Rummage JA; Rahimi MB; Herriott MJ
Immunobiology; 1986 Apr; 171(3):220-33. PubMed ID: 3519439
[TBL] [Abstract][Full Text] [Related]
29. Species restriction in cytostatic activity of human and murine monocytes and macrophages.
Hogg N; Balkwill FR
Immunology; 1981 May; 43(1):197-204. PubMed ID: 7251049
[TBL] [Abstract][Full Text] [Related]
30. Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.
Kleinerman ES; Wiltrout RH; Zicht R; Fidler IJ
Cancer Immunol Immunother; 1985; 20(2):151-7. PubMed ID: 3930068
[TBL] [Abstract][Full Text] [Related]
31. Mononuclear-cell infiltration in ovarian cancer. III. Suppressor-cell and ADCC activity of macrophages from ascitic and solid ovarian tumours.
Haskill S; Koren H; Becker S; Fowler W; Walton L
Br J Cancer; 1982 May; 45(5):747-53. PubMed ID: 6211187
[TBL] [Abstract][Full Text] [Related]
32. Activation of tumoricidal and/or suppressor macrophages: different stimulatory signals trigger either function both in vivo and in vitro.
Taramelli D; Bagley MB; Holden HT; Varesio L
Adv Exp Med Biol; 1982; 155():487-92. PubMed ID: 6218736
[No Abstract] [Full Text] [Related]
33. Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes.
Kleinerman ES; Fogler WE; Fidler IJ
J Leukoc Biol; 1985 May; 37(5):571-84. PubMed ID: 3920339
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of macrophage tumoricidal activity by the growth and differentiation factor CSF-1.
Ralph P; Nakoinz I
Cell Immunol; 1987 Apr; 105(2):270-9. PubMed ID: 2436807
[TBL] [Abstract][Full Text] [Related]
35. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
[TBL] [Abstract][Full Text] [Related]
36. In vitro modulation of macrophage tumoricidal activity: partial characterization of a macrophage-activating factor(s) in supernatants of NaIO4-treated peritoneal cells.
Weinberg JB; Hibbs JB
J Reticuloendothel Soc; 1979 Sep; 26(3):283-93. PubMed ID: 228037
[No Abstract] [Full Text] [Related]
37. Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity.
Ralph P; Nakoinz I; Rennick D
J Exp Med; 1988 Feb; 167(2):712-7. PubMed ID: 3126257
[TBL] [Abstract][Full Text] [Related]
38. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
39. Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl/6 mice: major NKT cell recruitment and increased cytotoxicity.
Ananias RZ; Rodrigues EG; Braga EG; Squaiella CC; Mussalem JS; Longhini AL; Travassos LR; Longo-Maugéri IM
Scand J Immunol; 2007 Jun; 65(6):538-48. PubMed ID: 17523946
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of macrophages grown in tumorous ascitic fluid.
Yamazaki M; Ikenami M; Yui S; Esumi-Kurisu M; Mizuno D
Gan; 1983 Feb; 74(1):155-61. PubMed ID: 6840434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
